Development of a high-performance liquid chromatographic method for bioequivalence study of flavoxate tablets

• Published in: Journal of chromatography. B, Biomedical sciences and applications Biomedical sciences and applications, 2001-02, Vol.751 (1), p.79-86
• Main Authors: Sheu, Ming-Thau, Yeh, Geng-Cheng, Ke, Wen-Ting, Ho, Hsiu-O
• Format: Article
• Language: English
• Subjects: Adult; Analysis; Biological and medical sciences; Chromatography, High Pressure Liquid - methods; Flavoxate; Flavoxate - analogs & derivatives; Flavoxate - blood; Flavoxate - pharmacokinetics; General pharmacology; Humans; Male; Medical sciences; Parasympatholytics - pharmacokinetics; Pharmacology. Drug treatments; Tablets; Therapeutic Equivalency
• ISSN: 0378-4347; 1387-2273
• DOI: 10.1016/S0378-4347(00)00451-5

An improved HPLC method was developed for the concentration determination of the metabolite of flavoxate, 3-methyl-flavone-8-carboxylic acid (MFCA), in plasma in an attempt to compare two flavoxate tablet formulations. This HPLC method was validated by examining the precision and the accuracy for inter-day and intra-day runs in a linear concentration range of 0.1–24 μg/ml. The coefficients of variation (C.V.) of inter-day and intra-day assays were 0.24–7.18% and 0.06–5.70%, respectively. The standard errors of mean (S.E.M.) were −0.004–8.68% and −2.52–4.86% for inter-day and intra-day assays, respectively. Bioequivalence of the two formulations was determined on 12 normal healthy male volunteers in a single-dose, two-period, two-sequence, two-treatment crossover study. MFCA plasma concentrations were analyzed with this validated HPLC method. The normal pivotal parameters, AUC 0–last, AUC 0–inf and C max, were calculated and compared using the SAS General Linear Model computer program. The two one-sided t distribution test was also performed, as well as the 90% confidence-interval method, for the mean difference of the three pivotal parameters. The results suggest that these two flavoxate tablet formulations are non-bioequivalent when orally administered in a 400-mg dose of two tablets. This result was consistent with the in vitro dissolution of these two formulations.